THEULTIMATED EDITIONUS 20170247762A1 TO THE MOUNTDOMAIN ( 19) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2017/ 0247762 A1 Heiman ( 43 ) Pub . Date: Aug . 31 , 2017 ( 54 ) COMPOSITIONS , METHODS AND USE OF Publication Classification SYNTHETIC LETHAL SCREENING (51 ) Int . CI. C120 1 /68 ( 2006 . 01 ) (71 ) Applicants : THE BOARD INSTITUTE INC ., C12N 15 / 113 ( 2006 .01 ) Cambridge, MA (US ) ; Massachusetts COZK 16 / 40 ( 2006 .01 ) Institute of Technology , Cambridge , A01K 67 /027 (2006 . 01 ) C12N 9 / 22 ( 2006 . 01 ) MA (US ) (52 ) U . S . CI. CPC . .. C12Q 1 /6883 (2013 . 01) ; A01K 67 /0278 (72 ) Inventor : Myriam Heiman , Newton , MA (US ) ( 2013 .01 ) ; C12N 9 / 22 ( 2013 .01 ) ; CO7K 16 / 40 ( 2013 .01 ) ; C12Y 111 /01009 ( 2013 . 01 ) ; C12N (21 ) Appl. No. : 15 /521 , 780 15 / 113 (2013 .01 ) ; AOIK 2267 / 0318 ( 2013 .01 ) ; C12Q 2600 / 118 ( 2013 . 01 ) ; C12Q 2600 / 158 (22 ) PCT Filed : Oct . 27 , 2015 (2013 .01 ) ; C120 2600 / 136 (2013 .01 ) ; C12N ( 86 ) PCT No. : PCT/ US2015 / 057567 2310 / 20 ( 2017 .05 ) ; CO7K 2317 / 34 (2013 .01 ) $ 371 ( C ) ( 1 ), (57 ) ABSTRACT Apr. 25 , 2017 The present invention generally relates to methods of iden ( 2 ) Date : tifying modulators of central nervous system diseases and the use of the modulators in treatment and diagnosis . The methods utilize a novel high throughput screen that includes Related U . S . Application Data injection of a library of barcoded viral vectors expressing (60 ) Provisional application No . 62/ 122, 686 , filed on Oct. shRNA ' s , CRISPR / Cas systems or cDNA ' s into animal 27 , 2014 . models of disease and detecting synthetic lethality . Patent Application Publication Aug. 31 , 2017 Sheet 1 of 10 US 2017 / 0247762 A1 Figure 1 D1 Cortex D2 Striatum D2 Cortex D1 Striatum Patent Application Publication Aug. 31 , 2017 Sheet 2 of 10 US 2017 / 0247762 A1 Figure 2 www wwwKX 11.13 ** h *** 1916 *** W ?ittirHig ** artement latorustusetaressingerplaintzituminiumtaprangolianteen tot ci bipolitsiit il : - OG 6414 wlimitilat Incubate in vivo dan * . " Pieetrit **** . * WWW fecupornoatérimeimariamartesoptimiertentie . atsing . wi Sitem .. .? . ? ... 15111 - 1 teatter - ... W printdorit . Hits,stifficial 4444444444444 Patent Application Publication Aug . 31, 2017 Sheet 3 of 10 _ US 2017/ 024776241 ? ??? ?? ?????? ?????? ?? .r r 1; -ir? "' ?: pxtt ????????????????????????? iif::: : :: : : ::?? : -: ????????: : -: :::: ????????????????????? ? ??!»:? otii ?????????? 143! !* * ??? ? ? ? ????????????? ??????????????????? %"??* ??????: r ?????; '-? : -: i ?????? ? ; ? 7? ?????? ???: xi ???????? i; : ? 1 ?F?????? ; »;riw * * ????? ? ? ?.. : ???????????? ? iii??????? ??????????????????? ???????w ;::- ? ??????? ? rfix ;k ? ? ? ? ??????????? 1? " ; ; 'P ; 'F r Wt ? ,??? }?lir?: 1.' ? ;?"vitir ? ? :*; ;?) it ?? ;;; ;! ! !! ! titity ?:1| ??? i : -????? nwkry ?:????????????? -i ??@ : ????? ??? ? ? ? ""'??????????? "" "t$: :: : 43 : ????? ? ?? ???: : : 'r tits ??????????????????????? , ?:?? : : ?. ???????? ::?: ????? »:??? ? ????????? : inary??? ??? Patent Application Publication Aug. 31 , 2017 Sheet 4 of 10 US 2017 / 0247762 A1 Figure 4 Mail W WI Merge . S Patent Application Publication Aug. 31 , 2017 Sheet 5 of 10 US 2017 / 0247762 Al 4. - 18 * ?????? { d { * da “ ? * s - rds -. eq ? *~ '{} -~ ?????# ? ? ~- & ~== *,"-. & Miss } **( ~ * ????? ????? ~ {{ ? # ????? # }'{ ????? ????? it, ???{}1{} » { ? ? *.* -fer } ?? ? ? **~ . - Y # ?????? {} ??{ ????? :-* * "{ $$$$* 24 **' ;+ $ ???? ++ = S? 14+ # xx? + # + ?? } } + # ft?y # -. ++ -:? ?????? +++ + ? 5 - - - - -- - - - Kdma { {{ { { { { {{ { $ $ $ 1231 ?? *?A } ? {} { } } { } {ca , | & -1 } Á¢8 ???? * 1:????? ????? » ? * ??????- } {13 * {13???????? $ * d d } * = 222 * * - s }{ $ “ ??? $ $ ? $ + { \{ 4 - s? } } $ ?????????? ????? - $ 4 $ ^ } } E ?h?? $ - ? $ ???? $ ????? }??} } } $ ¥¥¥¥? . ????? ,# x????? & } Rp # ????? "{{ ??????? T .+ { { 3 } se Change Fold ,Log { " }???£s ??? ? ???? { $ ) }11; c? * ? ? Patent Application Publication Aug. 31 , 2017 Sheet 6 of 10 US 2017 / 0247762 A1 Figure 6 Foooooooooo005 DalYoooooo000000000000000000000000 . Patent Application Publication Aug. 31 , 2017 Sheet 7 of 10 US 2017 / 0247762 A1 Figure ? # ** t Po # *** i 1 the at ** *MERE 1 2ter first * Wave** *** 14 Pons*** * lett ** within *# Med **** Aretu w ** C.C . Posterior 10000 ant cumPatent Applicationadinin Publication Augse. 31ne , 2017 un Sheetsasen 8 of 10 sanomatUS 2017 / 0247762 A1 Figure 8 Smatum 18 Months Hyoonalamus My Mopocampus MouseAge 1 Months wwwwwwwwwwwww 15 Months hassas wwwwwwwwwwwwww owow10000mgomo0o000000wowegoooooooooooooooooooooooooooong wowowowowow owowo 20 et Patent Application Publication Aug. 31 , 2017 Sheet 9 of 10 US 2017 / 0247762 A1 10 , 000 Figure 9A WT4 Conto 000 DW + Gpx *** * ** * * R6 / 2 + Control TotalDistance(cm) 8 . 900 Alifikimit*** * ** RR AIM * R6 /2 + Gore 7 . 003 *per mittittiteettttttttttAntiftitetits 6 ,000 ittimittittttning 5. 000 . dininiitsastustununP etiam Figure OB R6 /2 * Control ( left hemisphere ) R6 / 2 Gpx6 ( right hemisphere ) ?px6 DAPIS GPX6 EGEP DARPP :32 EGFPpooogooogooo DARPP 3 2 * www * * * * * * * Rt52 - ???? { Sispre 3 R6 /2 * Gpx6 ( right hemisphere ) DARPP.32Levels(AU wwwwwwwwwwww Patent Application Publication Aug . 31, 2017 Sheet 10 of 10 US 2017 /0247762 A1 Figure 10 20000 1 5000 TotalDistance(cm) 10000 5000 PD Gpx6 PD Control0000000 WT Control?? US 2017 /0247762 A1 Aug. 31, 2017 COMPOSITIONS , METHODS AND USE OF very difficult . Mental abilities generally decline into demen SYNTHETIC LETHAL SCREENING tia . Complications such as pneumonia , heart disease , and physical injury from falls reduce life expectancy to around RELATED APPLICATIONS AND twenty years from the point at which symptoms begin . There INCORPORATION BY REFERENCE is no cure for Huntington ' s disease , and full- time care is [ 0001] This application claims benefit of and priority to required in the later stages of the disease. U . S . provisional patent application Ser. No . 62 /122 ,686 , [ 0008 ] Treatments for Huntington ' s disease are available filed Oct. 27 , 2014 . to reduce the severity of some of its symptoms ( Frank et al . , [ 0002 ] The foregoing applications, and all documents (2010 ) Drugs 70 ( 5 ): 561 -71 ) . Tetrabenazine was approved cited therein or during their prosecution ( " appln cited docu in 2008 for treatment of chorea in Huntington ' s disease in ments” ) and all documents cited or referenced in the appln the United States . Other drugs that help to reduce chorea cited documents , and all documents cited or referenced include neuroleptics and benzodiazepines . Compounds such herein (“ herein cited documents ” ) , and all documents cited as amantadine are still under investigation but have shown or referenced in herein cited documents , together with any preliminary positive results (Walker , ( 2007 ) Lancet 369 manufacturer ' s instructions , descriptions, product specifica ( 9557 ) : 218 - 28 ) . Hypokinesia and rigidity , especially in tions , and product sheets for any products mentioned herein juvenile cases, can be treated with anti -Parkinson drugs , and or in any document incorporated by reference herein , are myoclonic hyperkinesia can be treated with valproic acid . hereby incorporated herein by reference , and may be employed in the practice of the invention . More specifically , [00091 Huntington ' s disease is caused by a mutation in the all referenced documents are incorporated by reference to Huntingtin gene . Expansion of a CAG ( cytosine - adenine the same extent as if each individual document was specifi guanine ) triplet repeat stretch within the Huntingtin gene cally and individually indicated to be incorporated by ref results in a mutant form of the protein , which gradually damages cells in the brain , through mechanisms that are not erence . fully understood . The length of the trinucleotide repeat FEDERAL FUNDING LEGEND accounts for 60 % of the variation in the age symptoms appear and the rate they progress. The remaining variation is [0003 ) This invention was made with government support due to environmental factors and other genes that influence under grant number NS085880 awarded by the National the mechanism of the disease (Walker , ( 2007) Lancet 369 Institutes of Health . The government has certain rights in the (9557 ) : 218 - 28 ) . invention . [ 0010 ] The diagnosis of Huntington ' s disease is suspected FIELD OF THE INVENTION clinically in the presence of symptoms. The diagnosis can be confirmed through molecular genetic testing which identi [ 0004 ] The present invention generally relates to methods fies the expansion in the Huntingtin gene . Testing of adults of identifying modulators of central nervous system diseases at risk for Huntington disease who have no symptoms using a novel high throughput methodology that includes (asymptomatic ) of the disease has been available for over expressing CRISPR / Cas systems, shRNA ' s or cDNA ' s in ten years . However , this testing cannot accurately predict the animal models of disease . age a person found to carry a Huntington disease causing mutation will begin experiencing symptoms, the severity or BACKGROUND OF THE INVENTION type of symptoms they will experience , or rate of disease [0005 ] Currently there are no cures or effective treatments progression . Other markers for disease progression are for many neurodegenerative diseases . All of the major available , for example , loss of DARPP - 32 striatal expression neurodegenerative diseases display characteristic